Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert

Seeking Alpha

Brett Scott » Articles |

Brett Scott picture

Brett Scott

Sort by:

Latest | Editors' Picks (2) | Most Commented | Most Popular

Understanding Cost of Capital in Biotechs' Valuation
on Jan 29, 2008
Will the Clouds Clear for Amgen?
on Jan 28, 2008 • AMGN
Gilead Keeps Going Strong
on Jan 25, 2008 • GILD
Correction and Clarification to Tysabri Post
on Jan 23, 2008 • BIIB, ELN, JNJ
Elan, Biogen Idec Won't Gain Much from Tysabri Approval
on Jan 21, 2008 • BIIB, ELN
Investors May Prefer to Stay Away from DNA
on Jan 15, 2008 • DNA
Forecast for ViroPharma's Pipeline: Mostly Shiny
on Jan 14, 2008 • VPHM
FDA Sets Date for Theravance Drug Review
on Jan 11, 2008 • THRX
A Win-Win for Isis, Genzyme in Cholesterol Drug Deal
on Jan 09, 2008 • GENZ, ISIS
Celgene Puts Drug Scare Behind It
on Jan 07, 2008 • CELG
Amgen's Bone Density Drug Needs to Prove Itself
on Dec 19, 2007 • AMGN
Three Reasons To Turn To Biotech In A Messy Market
on Nov 09, 2007 • BBH, IBB, PBE
Staph Buzz Spotlights Cubist, Pfizer, Encysive
on Oct 25, 2007 • CBST, ENCY, PFE
Gilead Continues To Shine, But Watch The Competition
on Oct 23, 2007 • GILD
3 Positives From Vanda's Conference Call
on Oct 11, 2007 • VNDA
NeurogesX, Vanda Would Do Well To Find Themselves A Partner
on Oct 01, 2007 • NGSX, VNDA
Two Important Lessons to be Learned from Sonus
on Sep 25, 2007 • SNUS
Celgene Offers Investors The Growth They Want
on Sep 16, 2007 • CELG
Is Biotech on the Verge of a Breakout?
on Sep 10, 2007 • BIIB
Now's The Time To Hop Aboard NeurogesX
on Sep 05, 2007 • NGSX
Sonus Is Undervalued At $4 - Call Options Are Attractive
on Aug 30, 2007 • SNUS
Vanda Pharmaceuticals: Finding Reassurance In Institutional Investors and Fair Value Calculations
on Aug 27, 2007 • VNDA
Helicos: To Buy or Not To Buy?
on Aug 23, 2007 • HLCS
Three Reasons to Be Optimstic on NeurogesX
on Aug 16, 2007 • NGSX
Vanda Pharmaceuticals' Pipeline Nearing FDA Stage
on Aug 14, 2007 • VNDA
Ziopharm: Too Early To Make A Call
on Jul 30, 2007 • ZIOP
Neurogesx: A Speculative Biotech Investment
on Jul 24, 2007 • NGSX
Genentech Suffering From A Lack of Short-Term Catalysts
on Jul 18, 2007 • DNA
DepoMed Demonstrates The Risks Of Small Biotech
on Jul 12, 2007 • DEPO
Celgene, Genentech, Gilead: Is Biotech Weakness Creating A Buying Opportunity?
on Jul 05, 2007 • CELG, DNA, GILD

Articles by Ticker

Latest Comments on Brett Scott's Articles

Critic on Will the Clouds Clear for Amgen?: Other than Amgen means many things to many people this doesnt say much more »
Tibcomonkey on Correction and Clarification to Tysabri Post: Brett, Thanks for correcting the Remicade error. I'm curious... more »
Let us be honest on Elan, Biogen Idec Won't Gain Much from Tysabri Approval: It is sad and pathetic and infuriating that the people who affect... more »
JohnnyRoger on Elan, Biogen Idec Won't Gain Much from Tysabri Approval: Brett, I am going to try to be charitable considering your... more »
SeekingAlpha Reader on Elan, Biogen Idec Won't Gain Much from Tysabri Approval: Let's see, on 1/7 Biogen announced that there were 20,400... more »
User 142431 on Elan, Biogen Idec Won't Gain Much from Tysabri Approval: Perhaps with more experience you will learn to look a little... more »
Tibcomonkey on Elan, Biogen Idec Won't Gain Much from Tysabri Approval: Brett, I'm sure J&J will be very concerned to learn they have... more »
Grayray on Elan, Biogen Idec Won't Gain Much from Tysabri Approval: Brett, Dr_Dave has done an excellent job in explaing the... more »
Dr_Dave on Elan, Biogen Idec Won't Gain Much from Tysabri Approval: Brett, You importantly failed to mention both cases of PML... more »
Beta Delta on Investors May Prefer to Stay Away from DNA: help is on the way for DNA.. ... the cavalry is rounding up its... more »
HarMegiddo on Forecast for ViroPharma's Pipeline: Mostly Shiny: well, that's where all the MRSA seem to be popping up, in high... more »
Shlomo Greenberg_ on Forecast for ViroPharma's Pipeline: Mostly Shiny: This article reads like a bad high school book report. more »
Zack Miller on Forecast for ViroPharma's Pipeline: Mostly Shiny: i miss shlomo greenberg. where did he go? more »
twinnkie on Amgen's Bone Density Drug Needs to Prove Itself: amgn will hit 90 by early 2009 more »
Amar Narayanan on Gilead Continues To Shine, But Watch The Competition: Your article has several factual errors. Just a couple of... more »

Latest Comments on Brett Scott's Articles